logo

ONLINE ACTIVITY

Multimodal Approaches to the Treatment of Mixed Pain

Layout 1

Release date: November 18, 2015
Expiration date: November 18, 2016

Estimated time to complete activity: 1 hour

For questions regarding your CME certificate, please contact www.pimed.com.

Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.

PIM-logo  MMC-logo-without-address

This activity is supported by an independent educational grant from Depomed, Inc.

Target Audience

This activity has been designed to meet the educational needs of health care professionals, physicians, registered nurses, and pharmacists involved in pain management.

Program Overview

The pathophysiology of many chronic pain syndromes involves both a neuropathic and a nociceptive component. Such chronic pain conditions, the so-called mixed pain syndromes, require both a careful assessment and a multimodal therapeutic approach. Mixed pain syndromes are very common and include a large proportion of low back pain, cancer pain, chronic postoperative pain, as well as most forms of osteoarthritis. A multimodal treatment approach may involve synchronous use of 2 or more agents with different mechanisms of action or the use of a single agent that works on multiple pain mechanisms. Since drug combinations create the possibility of drug-drug interactions, consideration should be given to drugs that are not metabolized through the P450 enzyme system. Any analgesic regimen that involves the use of an opioid should include principles of safe prescribing, including stratification of risk for opioid misuse.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe mixed pain syndromes based on an understanding of underlying pathophysiologic mechanisms
  • Select the most appropriate strategy to manage an individual's chronic pain, which may incorporate a multimodal approach
  • Implement strategies that minimize risk of abuse and limit adverse effects of analgesics, including opioids
  • Provide accurate and appropriate counsel as part of the treatment team
  • Provide appropriate care and counsel for patients and their families

Faculty

Oscar de Leon-Casasola, MD
Professor of Anesthesiology and Medicine
Senior Vice-Chair for Clinical Affairs
School of Medicine and Biomedical Sciences
University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
Buffalo, New York

Physician Continuing Medical Education Information

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Miller Medical Communications, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)(TM). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education Information

Accreditation Statement

630-acpe489469Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

The Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-15-292-H01-P)

Type of Activity

Application

Note: If you have participated in and claimed credit for the live version of this activity 0809-9999-15-245-H01-P, you are not eligible to receive credit for this activity.

Nursing Continuing Education Information

Credit Designation

This educational activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Oscar de Leon-Casasola, MD Consulting Fees: Daiichi Sankyo, Mallinckrodt, Purdue Pharma

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Lyerka Miller, PhD Nothing to disclose with regard to commercial interests

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Method of Participation and Request for Credit

There are no fees for participating in and receiving CME credit for this activity. During the period November 18, 2015, through November 18, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online.  If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 10999. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately.  Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.